NuCana plc

NASDAQ (USD): NuCana plc (NCNA)

Last Price

1.90

Today's Change

-0.02 (1.04%)

Day's Change

1.86 - 1.94

Trading Volume

65,202

Overview

Market Cap

4 Million

Shares Outstanding

2 Million

Avg Volume

1,401,732

Avg Price (50 Days)

4.00

Avg Price (200 Days)

5.18

PE Ratio

-0.11

EPS

-17.58

Earnings Announcement

14-Nov-2024

Previous Close

1.92

Open

1.89

Day's Range

1.8607 - 1.9399

Year Range

1.8607 - 20.25

Trading Volume

65,202

Price Change Highlight

1 Day Change

-1.04%

5 Day Change

-4.04%

1 Month Change

-32.86%

3 Month Change

-34.71%

6 Month Change

-67.80%

Ytd Change

-76.01%

1 Year Change

-87.01%

3 Year Change

-96.38%

5 Year Change

-98.82%

10 Year Change

-99.53%

Max Change

-99.53%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment